Tumor-specific shared antigenic peptides recognized by human T cells

Immunological Reviews

Volumn 188, Issue , 2002, Pages 51-64

  Van der Bruggen, Pierre ^a   Zhang, Yi ^a   Chaux, Pascal ^b   Stroobant, Vincent ^a   Panichelli, Christophe ^a   Schultz, Erwin S ^c   Chapiro, Jacques ^a   Van den Eynde, Benoît J ^a   Brasseur, Francis ^a   Boon, Thierry ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Oncodesign SA   (France)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; HLA ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; EPITOPE; HLA ANTIGEN; PEPTIDE FRAGMENT; SUBUNIT VACCINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC CODE; HUMAN; HUMAN CELL; ONCOGENE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN PROCESSING; RESTRICTION MAPPING; T LYMPHOCYTE ACTIVATION; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLASSIFICATION; CONSENSUS SEQUENCE; DENDRITIC CELL; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; MALE; MOLECULAR CLONING; MOLECULAR GENETICS; MULTIGENE FAMILY; NEOPLASM; REVIEW; T LYMPHOCYTE; TESTIS; X CHROMOSOME;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHROMOSOMES, HUMAN, X; CLONING, MOLECULAR; CONSENSUS SEQUENCE; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; NEOPLASMS; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TESTIS; TRANSDUCTION, GENETIC; VACCINES, SUBUNIT;

EID: 4444243096     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18806.x     Document Type: Article

References (111)

1. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P. Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
2. Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Exp Opin Biol Ther 2001;1:497-510.
3. Jäger E, Jäger D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol. 2002;14:178-182.
4. Marchand M, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
5. Thurner B, et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.
6. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729.
7. Haas GG Jr, D'Cruz OJ, De Bault LE. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 1988;18:47-51.
8. Pold M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR. Identification of a new, unorthodox member of the MAGE gene family. Genomics 1999;59:161-167.
9. Lucas S, Brasseur F, Boon T. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res 1999;59:4100-4103.
10. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-5551.
11. Boon T, Van den Eynde B. Cancer vaccines: Cancer antigens, shared tumor-specific antigens In: Rosenberg, SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd Edn. Philadelphia: JB Lippincott Williams & Wilkins, 2000:493-504.
12. van Baren N, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156-1164.
13. De Smet C, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE-1 gene. Immunogenetics 1995;42:282-290.
14. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996;93:7149-7153.
15. del Mazo J, Prantera G, Miguel T, Ferraro M. DNA methylation changes during mouse spermatogenesis. Chromosome Res 1994;12:147-152.
16. Hérin M, et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987;39:390-396.
17. Van den Eynde B, et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989;44:634-640.
18. Traversari C, et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992;35:145-152.
19. van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
20. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
21. Lucas S, De Plaen E, Boon T. MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: Four new members of the MAGE family with tumor-specific expression. Int J Cancer 2000;87:55-60.
22. De Plaen E, et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family Immunogenetics 1994;40:360-369.
23. Lurquin C, et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics 1997;46:397-408.
24. De Backer O, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999;59:3157-3165.
25. Muscatelli F, Walker AR De Plaen E, Stafford AN, Monaco AP. Isolation and characterization of a new MAGE gene family in the Xp21.3 region. Proc Natl Acad Sci USA 1995;92:4987-4991.
26. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science 1993;259:946-951.
27. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucl Acids Res 1994;22:5640-5648.
28. De Smet C, Martelange V, Lucas S, Brasseur F, Lurquin C, Boon T. Identification of human testis-specific transcripts and analysis of their expression in tumor cells. Biochem Biophys Res Commun 1997;241:653-657.
29. Lucas S, et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 1998;58:743-752.
30. Lethé B, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998;76:903-908.
31. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res 2000;60:3848-3855.
32. Sahin U, Türeci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-716.
33. - cell activation to a major mastocytoma rejection antigen, P815AB. Requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 1995;25:2797-2802.
34. Ossendorp F, Mengede E, Camps M, Filius R, Melief C. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibllity complex class II negative tumors. J Exp Med 1998;187:693-702.
35. Natali P, et al. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Hum Immunol 1986;15:220-233.
36. Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, Parmiani G. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 1986;46:433-439.
37. + T cell responses in antitumor immunity. Curr Opin Immunol 1998:10:588-594.
38. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: First listing. Immunogenetics 1995;41:178-228.
39. Marsh SGE, Parham P, Barber LD. The HLA Factsbook. Factsbook Series. London: Academic Press, 2000.
40. Rammensee H-G, Bachmann J, Stevanovic S. MHC ligands and peptide motifs. In: Molecular Biology Intelligence Unit. New York: Springer, 1997.
41. Hammer J, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993;74:197-203.
42. Sturniolo T, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnol 1999;17:555-561.
43. Romani N, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
44. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994;179:1109-1118.
45. + T lymphocytes. J Exp Med 1999;189:767-777.
46. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci USA 1995;92:7217-7221.
47. van der Bruggen P, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-3043.
48. Herman J, et al. A peptide encoded by the human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics 1996;43:377-383.
49. Skipper JCA, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
50. Meadows L, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997;6:273-281.
51. Valmori D, et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 1999;189:895-906.
52. Kessler JH, et al. Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
53. Pascolo S, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 2001;61:4072-4077.
54. Barnea E, et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: A novel approach for identifying tumor-specific antigens. Eur J Immunol 2002;32:213-222.
55. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999;29:964-972.
56. Jonuleit H, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-3142.
57. Taylor J, et al. Efficacy studieson a canarypox-rabies recombinant virus. Vaccine 1991;9:190-193.
58. Arthur JF, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17-25.
59. Duffour M-T, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen PA MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 1999;29:3329-3337.
60. Van Tendeloo VF, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells, superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
61. Cornelis GR, Van Gijsegem F. Assembly and function of type III secretory systems. Annu Rev Microbiol 2000;54:735-774.
62. Boland A, Cornelis GR. Role of YopP in suppression of Tumor Necrosis Factor alpha release by macrophages during Yersinia infection. Infect Immun 1998;66:1878-1884.
63. Chaux P, et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999;163:2928-2936.
64. Luiten R, van der Bruggen P. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens 2000;55:149-152.
65. Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 2000;56:77-81.
66. Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus: Implications for the expression of HLA-C. J Exp Med 1992;176:937-950.
67. van der Bruggen P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-2140.
68. Traversari C, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
69. Boël P, et al. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
70. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
71. Gangler B, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
72. Luescher IF, et al. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. J Biol Chem 1996;271:12463-12471.
73. Coulie PG, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001;98:10290-10295.
74. Schultz ES, et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 2001;57:103-109.
75. Tussey LG, et al. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995;3:65-77.
76. + T cell responses. J Immunol 1999;163:5820-5826.
77. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999;189:871-876.
78. + cytolytic T lymphocytes. Cancer Res 2000;60:6272-6275.
79. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class 1-presented peptides. Annu Rev Immunol 1999;17:739-779.
80. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 1999;29:4037-4042.
81. Morel S, et al. Processing of some antigens by the standard proteasome but not by the immtmoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-117.
82. Toes REM, et al. Discrete deavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001;194:1-12.
83. Driscoll J, Brown M, Finley D, Monaco J. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
84. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM. Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol 1995;25:2605-2611.
85. Van den Eynde BJ, Morel S. Differential processing of class-1-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 2001;13:147-153.
86. Schultz ES, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med 2002;195:391-399.
87. Chen J-L, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000;165:948-955.
88. Chen Y-T, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
89. Türeci Ö, et al. The SSX-2 gene, which is involved in the t (X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996;56:4766-4772.
90. Türeci Ö, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1998;95:5211-5216.
91. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier Pl. Interleukin-2-induced, melanoma-specific T cells recognize camel, an unexpected translation product of LAGE-1. Int J Cancer 1999;82:442-448.
92. Jäger E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
93. Rimoldi D, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immmunol 2000;165:7253-7261.
94. Wang R-F, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998;161:3596-3606.
95. Gnjatic S, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000;97:10917-10922.
96. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000;191:625-630.
97. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153-1159.
98. + T cells. Cancer Res 2000;60:4946-4952.
99. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi TA MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999;80:169-172.
100. Tanzarella S, et al. Identification of a promiscuous T cell epitope encoded by multiple members of the MAGE family. Cancer Res 1999;59:2668-2674.
101. + T cells. Eur J Immunol 2001;31:1910-1916.
102. Kawashima I, et al. The multi-epitope approach for immunotherapy for cancer. Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14.
103. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lyaphocytes. Clin Cancer Res 1999;5:2236-2241.
104. Tanaka F, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997;57:4465-4468.
105. Oiso M, et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer 1999;81:387-394.
106. Russo V, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 2000;97:2185-2190.
107. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E, Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001;61:4773-4778.
108. Zorn E, Hercend TA MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma. Eur J Immunol 1999;29:602-607.
109. Huang L-Q, et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immmol 1999;162:6849-6854.
110. Heidecker L, Brasseur F, Probst-Kepper M, Guéguen M, Boon T, Van den Eynde BJ. Cytolytic T lymphocytes raised against a human bladder carcinoma encoded by gene MAGE-A12. J Immunol 2000;164:6041-6045.
111. Panelli MC, et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognize MAGE-12. J Immunol 2000;164:4382-4392.